Minghui Pharma Enters into $1.85B B7-H3 ADC Licensing Deal with Qilu Pharma; First Domestic Long-Acting Analgesic Approved in China
Qilu Pharmaceutical
Specialty Formulations and Active Pharmaceutical Ingredients (API) Developer
Sirius Therapeutics
Oligonucleotide Drug Developer
Abogen
Nucleic Acid Drug Developer
Fosun Pharmaceutical
Healthcare Industry Group
Johnson & Johnson
Medical Device R&D and Manufacturer
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
© Amino Observation - Innovative Drug Team Original Production
Author | Huang Kai
Acceleration of Intramolecular Circulation in China-Produced Products.
On May 9, Minghui Pharmaceutical announced an exclusive licensing and collaboration agreement with Qilu Pharmaceutical, granting the latter rights to develop, manufacture, and commercialize its B7-H3 ADC drug MHB088C in Greater China.
Minghui Pharmaceutical Ltd. is expected to receive total payments of up to 1.345 billion RMB, including an upfront payment of 280 million RMB and recent milestone payments, as well as development, regulatory, and sales milestone payments amounting to 1.065 billion RMB, along with net product sales royalties in the double-digit range.
China's First Long-Acting Painkiller New Drug Approved for Marketing.
On May 9, according to the NMPA website, Nanjing Qingpu Biotech's Meloxicam Injection (QP001) was approved for marketing in China, with a single injection providing 24 hours of sustained and potent pain relief.
In the past day, what are the hot topics in the pharmaceutical markets at home and abroad that are worth paying attention to? Let Amino take you to explore.
/ 01 /
Market Express
1) Minghui Pharmaceutical and Qilu Pharmaceutical Reach Licensing Collaboration on B7-H3 ADC
On May 9, Minghui Pharmaceutical announced an exclusive licensing and cooperation agreement with Qilu Pharmaceutical, granting the latter rights to develop, manufacture, and commercialize its B7-H3 ADC drug MHB088C in Greater China. Minghui Pharmaceutical is eligible to receive total payments of up to 1.345 billion RMB, including an upfront payment and near-term milestone payments totaling 280 million RMB, development, regulatory, and sales milestone payments amounting to 1.065 billion RMB, as well as tiered royalties in the double-digit percentages on net product sales.
/ 02 /
Capital Information
1) Sirius Therapeutics Completes Nearly 50 Million USD Financing
On May 9, Sirius Therapeutics announced the successful completion of a nearly 50 million USD B2 round of financing to accelerate the clinical development of its novel small interfering RNA (siRNA) therapy for cardiometabolic diseases and to continue innovating its next-generation RNA delivery technology.
/ 03 /
Pharmaceutical News
1) Abogen's mRNA Therapeutic Cancer Vaccine Receives FDA Clinical Approval
On May 9, Abogen announced that its self-developed novel mRNA cancer vaccine, which simultaneously covers multiple KRAS mutations, has officially received FDA clinical trial approval. It is applicable to patients with solid tumors carrying any of the five common KRAS mutations.
2) MWN109 Tablets by Minghui Pharmaceutical Receive Clinical Approval
On May 9, according to the CDE official website, Minwei Biotech's MWN109 tablet received clinical approval and is planned to conduct research for the treatment of overweight or obesity.
3) Fosun Pharmaceutical's Subsidiary Junji Health Receives FDA Clinical Approval
On May 9, Fosun Pharmaceutical announced that its holding subsidiary, Junji Health, had received approval from the U.S. FDA to conduct clinical trials for LBP-ShC4, intended for the treatment of androgenetic alopecia.
4) The first IL-23 inhibitor for the treatment of UC approved in China
On May 9, Johnson & Johnson announced that Tremfya and Trevoza had been approved in China for the treatment of adult patients with moderate to severe active ulcerative colitis (UC) who have had an inadequate response, lost response, or are intolerant to conventional therapies or biologics. This is China's first IL-23 inhibitor for the treatment of UC.
5) RemeGen's Disitamab Vedotin Approved for Treating Breast Cancer Patients with Liver Metastasis
On May 9, Rongchang Bio announced that Disitamab Vedotin has been approved for a new indication, used to treat HER2-positive advanced breast cancer patients with liver metastases.
6) China's First Long-Acting Painkiller New Drug Approved for Marketing
On May 9, according to the NMPA website, Nanjing Qingpu Biotech's Meloxicam Injection (QP001) was approved for marketing. This is the first long-acting analgesic new drug in China, with a single injection providing 24 hours of continuous and potent pain relief.
7) CAR-T Cell Therapy Injection from Reindeer Bio Receives Orphan Drug Designation from Saudi Arabia FDA
On May 9, IASO Bio announced that the Saudi Arabia Food and Drug Administration (Saudi FDA) has granted orphan drug designation to its self-developed BCMA-targeting CAR-T cell therapy product, Equecabtagene Autoleucel Injection, for the treatment of adult patients with relapsed or refractory multiple myeloma who have progressed following at least three prior lines of therapy.
/ 04 /
Overseas Pharmaceutical News
1) AstraZeneca's PD-L1 Monoclonal Antibody Succeeds in a Phase III Study
On May 9, AstraZeneca announced that the Phase III POTOMAC study of Imfinzi in combination with standard of care (SOC) for the treatment of high-risk non-muscle-invasive bladder cancer (NMIBC) patients achieved positive high-level results.
PS: Welcome to scan the QR code below to add Amino's WeChat for communication.